Canada markets open in 7 hours 27 minutes

Sutro Biopharma, Inc. (S09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
3.4400+0.2200 (+6.83%)
As of 03:29PM CEST. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 302.03M
Enterprise Value -18.59M
Trailing P/E 82.31
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.35
Price/Book (mrq)1.89
Enterprise Value/Revenue -0.12
Enterprise Value/EBITDA 0.32

Trading Information

Stock Price History

Beta (5Y Monthly) 0.98
52-Week Change 3-31.78%
S&P500 52-Week Change 321.33%
52 Week High 35.4500
52 Week Low 31.9100
50-Day Moving Average 33.9620
200-Day Moving Average 33.6069

Share Statistics

Avg Vol (3 month) 3N/A
Avg Vol (10 day) 3N/A
Shares Outstanding 581.76M
Implied Shares Outstanding 689.04M
Float 849.42M
% Held by Insiders 10.90%
% Held by Institutions 178.91%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -69.47%
Operating Margin (ttm)37.94%

Management Effectiveness

Return on Assets (ttm)-12.71%
Return on Equity (ttm)-58.25%

Income Statement

Revenue (ttm)153.73M
Revenue Per Share (ttm)2.56
Quarterly Revenue Growth (yoy)1,217.40%
Gross Profit (ttm)N/A
EBITDA -82.46M
Net Income Avi to Common (ttm)-106.79M
Diluted EPS (ttm)-1.6600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)375.62M
Total Cash Per Share (mrq)6.01
Total Debt (mrq)33.63M
Total Debt/Equity (mrq)22.48%
Current Ratio (mrq)4.50
Book Value Per Share (mrq)2.45

Cash Flow Statement

Operating Cash Flow (ttm)-111.62M
Levered Free Cash Flow (ttm)-30.58M